Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxazosin for Co-Occurring PTSD and Alcohol Use Disorders
NCT02500602Phase 2Completed
- Sponsor
- VA Office of Research & Development
- Start
- Jun 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-traumatic stress disorder (PTSD), alcohol use disorder (AUD) and substance use disorder (SUD) comparing Doxazosin with Placebo (2 arms). Primary endpoints: Clinician Administered PTSD Scale at 12 weeks, PTSD Checklist at 12 weeks and 1 more. Started Jun 2016; status: completed.
02
Drugs
doxazosin
03
Conditions
post-traumatic stress disorder (PTSD)alcohol use disorder (AUD)substance use disorder (SUD)
Beyond the preview
Go deeper on NCT02500602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500602.